Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

PURPOSE: Ribociclib has provided significant improvements in progression-free survival (PFS) and overall survival (OS) of postmenopausal patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). However, given the high cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jiangping, Han, Jiaqi, Tian, Maolang, Tian, Kun, Liao, Wenjun, Yan, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751309/
https://www.ncbi.nlm.nih.gov/pubmed/33364838
http://dx.doi.org/10.2147/CMAR.S284556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751309/
https://www.ncbi.nlm.nih.gov/pubmed/33364838
http://dx.doi.org/10.2147/CMAR.S284556

Ejemplares similares